Form 4: Recursion Pharmaceuticals Director Sells Shares
Insider Transaction (Form 4)
Robert Hershberg, a Director of Recursion Pharmaceuticals, Inc., sold 25,000 shares of common stock on October 6, 2026 for $5.00 per share.
Summary
- Option exercise/conversion: acquired 25,000 Class A Common Stock at $2.22 ($55,500) on October 6, 2026; holds 187,156 after (Direct).
- Open-market sale: disposed of 25,000 Class A Common Stock at $5.00 ($125,000) on October 6, 2026; holds 162,156 after (Direct).
- Option exercise/conversion: disposed of 25,000 Stock Option (Right to Buy) at $2.22 ($55,500) on October 6, 2026; holds 500,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $125,000 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Robert Hershberg — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-06 | Option exercise/conversion | Class A Common Stock | 25,000 | $2 | $55.5K | 187,156 |
| 2026-10-06 | Open-market sale | Class A Common Stock | 25,000 | $5 | $125.0K | 162,156 |
| 2026-10-06 | Option exercise/conversion | Stock Option (Right to Buy) | 25,000 | $2 | $55.5K | 500,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-06 | Option exercise/conversion (25,000 shares) |
| 2026-10-06 | Open-market sale (25,000 shares) |
| 2026-10-06 | Option exercise/conversion (25,000 shares) |
Keywords
insider transaction, Form 4, RXRX, RECURSION PHARMACEUTICALS, INC., bearish, Robert Hershberg
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.